Abata Therapeutics Receives Investment from BMS for the Advancement of Treg Cell Therapies
Shots:
- Abata Therapeutics reported that to further develop its Treg cell therapy products the company received an equity investment from BMS
- The investment was focused on supporting the clinical products of the company, starting from ABA-101 for the treatment of progressive multiple sclerosis and ABA-201 for the treatment of type 1 diabetes
- Both indications are tissue-specific autoimmune diseases and ABA-101 & ABA-201 are developing through the Treg cell therapy
Ref: Abata Therapeutics | Image: Abata Therapeutics
Related Posts:- Abata Therapeutics Reports the US FDA’s IND Clearance for P-I Trial of ABA-101 for Progressive Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
